750 related articles for article (PubMed ID: 31875625)
1. [Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States].
Kato M; Ishikawa H; Okuhara T; Kiuchi T
Nihon Koshu Eisei Zasshi; 2019; 66(12):746-755. PubMed ID: 31875625
[TBL] [Abstract][Full Text] [Related]
2. Transparent collaboration between industry and academia can serve unmet patient need and contribute to reproductive public health.
D'Hooghe T
Hum Reprod; 2017 Aug; 32(8):1549-1555. PubMed ID: 28854594
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical Industry Support of US Patient Advocacy Organizations: An International Context.
Kang SY; Bai G; Karas L; Anderson GF
Am J Public Health; 2019 Apr; 109(4):559-561. PubMed ID: 30789768
[TBL] [Abstract][Full Text] [Related]
4. Patient organizations' funding from pharmaceutical companies: is disclosure clear, complete and accessible to the public? An Italian survey.
Colombo C; Mosconi P; Villani W; Garattini S
PLoS One; 2012; 7(5):e34974. PubMed ID: 22590498
[TBL] [Abstract][Full Text] [Related]
5. Corporate Social Responsibility Disclosure: Responding to Investors' Criticism on Social Media.
Zhang Y; Yang F
Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34299847
[TBL] [Abstract][Full Text] [Related]
6. Public health and corporate social responsibility: exploratory study on pharmaceutical companies in an emerging market.
Dănescu T; Popa MA
Global Health; 2020 Dec; 16(1):117. PubMed ID: 33302949
[TBL] [Abstract][Full Text] [Related]
7. Advertising and disclosure of funding on patient organisation websites: a cross-sectional survey.
Ball DE; Tisocki K; Herxheimer A
BMC Public Health; 2006 Aug; 6():201. PubMed ID: 16887025
[TBL] [Abstract][Full Text] [Related]
8. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
9. Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
Pashley D; Ozieranski P; Mulinari S
Int J Health Serv; 2022 Jul; 52(3):347-362. PubMed ID: 35230175
[TBL] [Abstract][Full Text] [Related]
10. Commitments by the biopharmaceutical industry to clinical trial transparency: the evolving environment.
Baronikova S; Purvis J; Southam E; Beeso J; Panayi A; Winchester C
BMJ Evid Based Med; 2019 Oct; 24(5):177-184. PubMed ID: 30898790
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan.
Saito H; Ozaki A; Sawano T; Shimada Y; Tanimoto T
JAMA Netw Open; 2019 Apr; 2(4):e192834. PubMed ID: 31026027
[TBL] [Abstract][Full Text] [Related]
12. Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: Analysis of payment data in 2016.
Ozaki A; Saito H; Senoo Y; Sawano T; Shimada Y; Kobashi Y; Yamamoto K; Suzuki Y; Tanimoto T
Health Policy; 2020 Jul; 124(7):727-735. PubMed ID: 32439213
[TBL] [Abstract][Full Text] [Related]
13. International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency.
Ozieranski P; Saito H; Rickard E; Mulinari S; Ozaki A
Global Health; 2023 Mar; 19(1):14. PubMed ID: 36869318
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK.
Rickard E; Ozieranski P; Mulinari S
Health Policy; 2019 Dec; 123(12):1244-1250. PubMed ID: 31455562
[TBL] [Abstract][Full Text] [Related]
15. Corporate social responsibility to improve access to medicines: the case of Brazil.
Thorsteinsdóttir H; Ovtcharenko N; Kohler JC
Global Health; 2017 Feb; 13(1):10. PubMed ID: 28222793
[TBL] [Abstract][Full Text] [Related]
16. Private-sector research ethics: marketing or good conflicts management? The 2005 John J. Conley Lecture on Medical Ethics.
Dresser R
Theor Med Bioeth; 2006; 27(2):115-39. PubMed ID: 16699963
[TBL] [Abstract][Full Text] [Related]
17. Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe.
Ozieranski P; Martinon L; Jachiet PA; Mulinari S
Int J Health Policy Manag; 2022 Dec; 11(12):2842-2859. PubMed ID: 35297231
[TBL] [Abstract][Full Text] [Related]
18. Comparation of differences in the performance of corporate social responsibility between Chinese and American pharmaceutical enterprises-based on corporate social responsibility report.
Xu H; Zhang M; Chu S
Front Pharmacol; 2023; 14():1116466. PubMed ID: 37284320
[No Abstract] [Full Text] [Related]
19. Impact of China's Vaccine Incidents on the Operational Efficiency of Biopharmaceutical Companies.
Chai KC; Tao R; Chang KC; Yang Y
Front Public Health; 2020; 8():93. PubMed ID: 32322567
[No Abstract] [Full Text] [Related]
20. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
